European Conference on
Pharmacovigilance & Drug Safety
November 18-19, 2019 | Prague, Czech Republic

Scientific Program
Day 1  
November 18, 2019

08:30-09:30  Registrations

Meeting Hall @ Eden

Keynote Forum

09:50-10:00  Introduction

10:00-10:45  The role of clinical trials pharmacist in study medication adherence  
Eugenia Hong, The Royal Melbourne Hospital Clinical Trials Pharmacy, Australia

10:45-11:30  Investigation of Efavirenz discontinuation in multi-ethnic populations of HIV-positive individuals by genetic analysis  
Cummins Nathan W., Mayo Clinic, USA

Networking and Refreshment Break 11:30-11:45 @ Corridor

11:45-12:30  Postmarketing safety surveillance program results of the first Russian interferon beta-1b biosimilar  
Alexey Skripkin, BIOCAD, Russia

Sessions: Pharmacovigilance Scope & Significance | Pharmacovigilance Risk Management | Drug Safety
Session Chair: Eugenia Hong, The Royal Melbourne Hospital Clinical Trials Pharmacy, Australia  
Session Co-Chair: Mario Bertazzoli, Helsinn Healthcare SA, Switzerland

Session Introduction

12:30-13:00  Unique challenges and opportunities in conducting Pharmacovigilance for orphan drug  
Cristina Damatarca, Agility Clinical, USA

13:00-13:30  Netupitant-palonosetron: Safety profile of a novel fixed-dose combination drug in the prevention of chemotherapy induced nausea and vomiting  
Mario Bertazzoli, Helsinn Healthcare SA, Switzerland

Group Photo

Lunch Break 13:30-14:15 @ Mezzo Restaurant

14:15-14:45  Consumer acceptance of mobile-assisted smoking cessation programs  
Silvia Cacho-Elizondo, IPADE Business School, USA

Sessions: Regulatory Affairs in Pharmaceutical Industry | Pharma and Health Care Advertising | Industrial | Hazards and Safety Measures

14:45-15:15  Self-medication  
Csilla Major, Semmelweis University, Hungary

15:15-15:45  Fabrication of high-valent silver nanoparticles as topical antibacterial agent  
Joon Myong Song, Seoul National University, Korea

15:45-16:15  Considerations in innovative clinical study design for China development and registration  
Nicole F Li, Roche Pharmaceuticals, China

16:15-16:45  Toxicology as a standard step in the regulations of Pharmaceutical industry  
Medani Amna Beshir, University of Medical Sciences & Technology, Sudan

Networking and Refreshment Break 16:45-17:00 @ Corridor

Sessions: Preclinical and Clinical Trials | Data Quality Management and Analysis

17:00-17:30  Mechanism of high MW complexes formation by Verteporfin which can impair the growth of cancer cells  
Eleni Konstantinou, Harvard Medical School, USA

17:30-18:00  Impedance spectroscopy for the non-destructive evaluation of in vitro epidermal models  
Lisa Engelhardt, University of Würzburg, Germany

Panel Discussion

Day 2  
November 19, 2019

Meeting Hall @ Eden

Sessions: Drug safety | Pharmacy Practice & Challenges | Preclinical and Clinical Trials on various disorders
Session Chair: Lasse Lehtonen, Helsinki University Hospital, Finland  
Session Co-Chair: Mario Bertazzoli, Helsinn Healthcare SA, Switzerland

Session Introduction
**10:00-10:30**

**Is Carnitine deficiency the cause of higher Ammonia levels in patients under Valproic acid treatment and in the elderly?**  
*Cecilia Maldonado*, Universidad de la República, Uruguay

**Limited value of relative risk reductions for assessing the benefits of disease-modifying therapies for multiple sclerosis**  
*Magd Zakaria*, Ain Shams University, Egypt


---

**Networking and Refreshment Break 11:00-11:15 @ Corridor**

---

**11:15-11:45**

**Developing a method for identifying a university hospital’s high-alert medications**  
*Lasse Lehtonen*, Helsinki University Hospital, Finland

**Ensuring perioperative and PACU drug safety**  
*A D John*, Johns Hopkins University School of Medicine, USA

**Overcoming challenges in conducting clinical trials in Egypt- 10 years experience**  
*Nihal El Habachi*, Alexandria University School of Medicine, Egypt

---

**Lunch Break 12:45-13:45 @ Mezzo Restaurant**

---

**Poster Presentation Session 13:45-14:45 @ Foyer**

**PVC01 Specialized U.S. Food and Drug Administration Investigators for enhanced protection of public health**  
*Chrissy Cochran*, USFDA, USA

**PVC02 Nimesulide benefit-risk assessment: How to keep under control the safety profile of a mature drug**  
*Mario Bertazzoli*, Helsinn Healthcare SA, Switzerland

**PVC03 Pharmacological evaluation of α-1-adrenolytics in patients diagnosed with benign prostatic hyperplasia**  
*Tomasz Ząbkowski*, Military Medical Institute, Poland

**PVC04 Synthesis of novel chromene derivatives of expected antitumor activity**  
*Manal M Kandeel*, Future University, Egypt

**PVC05 Aliskiren attenuated hypoxia-induced cardiac injury through activation of autophagy**  
*Yuh-Lien Chen*, National Taiwan University, Taiwan

**PVC06 Novel instantly-soluble transmucosal matrix (ISTM) using dual mechanism solubilizer for sublingual and nasal delivery of dapoxetine hydrochloride: In-vitro/in-vivo evaluation**  
*Shahinaze A. Fouad*, Ahram Canadian University, Egypt

**PVC07 Can Donepezil facilitate weaning from mechanical ventilation in difficult to wean patients? An interventional pilot study**  
*Kamran Fazel*, Bagiatalla University of Medical Sciences, Iran

**PI01 Design and manufacture of applicable delivery system for toxic drugs**  
*Zhijun Yang*, Baptist University, Hong Kong

**PI02 Healthcare system across Europe and USA: The market-access agreement experience**  
*Eleonora Allocati*, Annunzio University, Italy

---

**Sessions: Drug safety | Pharmacy Practice & Challenges | Preclinical and Clinical Trials on various disorders**

**14:45-15:15**

**Medication administration errors in paediatric ward: Observational study**  
*Zayed Nama Al Sulami*, Alkharji Military Industries Corporation Hospital, Saudi Arabia

**15:15-15:45**

**Analysis of off-label use of drugs among pediatric inpatients of a tertiary care teaching hospital**  
*Mangesh Banker*, Andaman & Nicobar Islands Institute of Medical Sciences, India

---

**Networking and Refreshment Break 15:45-16:00 @ Meetings Halls**

---

**16:00-16:15**

**Falsified medicines: Past, present and future**  
*Lain Abril, Julia*, San Pablo University, Spain

**16:15-16:30**

**C1- inhibitors (Berinert®) versus Icatibant in the treatment of hereditary angioedema**  
*Silvia Leone*, University in Genoa, Italy

**Development of HPLC-UV/MS-MS methods applied to the quality control of Ursodeoxycholic acid in oral liquid pediatric formulations and raw material**  
*Oriana Boscolo*, University of BuenosAires, Argentina.

**16:45-17:00**

**Architectural plans in drug facilities are the first step to attain safer drug industry**  
*Saria Galal*, National University of Arribat, Sudan

---

**Awards & Closing ceremony**

---

**Extended Networking & B2B Meetings**

**End of Day 2**